Rakuten Securities Inc. Increases Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Rakuten Securities Inc. increased its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 270,525.0% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 10,825 shares of the company’s stock after purchasing an additional 10,821 shares during the quarter. Rakuten Securities Inc.’s holdings in Elanco Animal Health were worth $159,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. 180 Wealth Advisors LLC boosted its stake in Elanco Animal Health by 3.6% during the second quarter. 180 Wealth Advisors LLC now owns 25,716 shares of the company’s stock valued at $352,000 after buying an additional 893 shares during the period. HBK Sorce Advisory LLC boosted its stake in Elanco Animal Health by 9.4% during the second quarter. HBK Sorce Advisory LLC now owns 12,920 shares of the company’s stock valued at $186,000 after buying an additional 1,107 shares during the period. Atomi Financial Group Inc. boosted its stake in Elanco Animal Health by 11.1% during the second quarter. Atomi Financial Group Inc. now owns 12,260 shares of the company’s stock valued at $177,000 after buying an additional 1,221 shares during the period. Keene & Associates Inc. boosted its stake in Elanco Animal Health by 5.7% during the third quarter. Keene & Associates Inc. now owns 22,945 shares of the company’s stock valued at $337,000 after buying an additional 1,240 shares during the period. Finally, Resonant Capital Advisors LLC boosted its stake in Elanco Animal Health by 5.0% during the second quarter. Resonant Capital Advisors LLC now owns 27,325 shares of the company’s stock valued at $394,000 after buying an additional 1,306 shares during the period. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Barclays lifted their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday. Morgan Stanley cut Elanco Animal Health from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $17.00 to $15.00 in a report on Thursday, September 19th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $20.00 price objective on shares of Elanco Animal Health in a report on Thursday, September 19th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $17.14.

Insider Activity at Elanco Animal Health

In other news, Director Michael J. Harrington purchased 3,500 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were acquired at an average price of $14.85 per share, with a total value of $51,975.00. Following the acquisition, the director now directly owns 81,094 shares in the company, valued at approximately $1,204,245.90. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.57% of the stock is owned by insiders.

Elanco Animal Health Price Performance

ELAN stock opened at $14.27 on Tuesday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.75 and a current ratio of 2.93. Elanco Animal Health Incorporated has a 52 week low of $10.42 and a 52 week high of $18.80. The firm’s fifty day moving average is $13.90 and its 200 day moving average is $14.75. The firm has a market cap of $7.05 billion, a P/E ratio of 35.66, a P/E/G ratio of 1.47 and a beta of 1.41.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Thursday, November 7th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.91%. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same quarter last year, the firm earned $0.18 EPS. The firm’s quarterly revenue was down 3.6% compared to the same quarter last year. Research analysts predict that Elanco Animal Health Incorporated will post 0.92 earnings per share for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.